The funding will allow us to further advance our most promising portfolio of diagnostic imaging products, providing healthcare professionals with new products that expand and improve their diagnostic capabilities
Atlanta, GA (PRWEB) December 21, 2011
MissionIR would like to highlight FluoroPharma Medical, Inc. (OTCBB: FPMI). FluoroPharma Medical is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products in clinical trials to fulfill critical unmet medical needs.
In the company’s news yesterday,
FluoroPharma Medical, Inc. announced that they have secured an additional $1.010 million, bringing the total to more than $7 million over the course of 2011 from institutional and accredited investors.
“We are excited by the opportunities this additional working capital creates for FluoroPharma to significantly accelerate development of our pipeline,” stated Thijs Spoor, FluoroPharma’s President and CEO. “The funding will allow us to further advance our most promising portfolio of diagnostic imaging products, providing healthcare professionals with new products that expand and improve their diagnostic capabilities and contribute to earlier, more accurate diagnosis and treatment of disease– even before symptoms appear.”
Dr. David Elmaleh, Chairman of FluoroPharma’s Board of Directors added, “We are pleased that we have the resources to advance our clinical plans and achieve significant development milestones.”
Further details of the additional funds raised are available in the company’s most recent 8k.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.